LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance

U.S. Markets close in 1 hr 57 mins

Eli Lilly and Company (LLY)

NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
66.92-0.79 (-1.17%)
As of 2:03 PM EST. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close67.71
Bid66.98 x 1100
Ask67.00 x 1000
Day's Range66.74 - 68.31
52 Week Range64.18 - 88.16
Avg. Volume5,327,546
Market Cap70.62B
PE Ratio (TTM)29.11
Earnings DateN/A
Dividend & Yield2.04 (3.01%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist4 hours ago

    Why Did the S&P 500 Post Moderate Gains on December 2?

    The S&P 500 closed moderately higher on December 2 amid soft job data. The utilities and consumer staples sectors supported the S&P 500 on December 2.

  • 24/7 Wall St.6 hours ago

    4 Merrill Lynch Med Tech and Drug Dividend Stocks to Buy With Huge 2017 Potential

    These are stocks that make good sense for investors looking to add to their overall equity holdings. They are all trading well below their 52-week highs and should be attracting substantial institutional ...

  • PR Newswire6 hours ago

    U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

    RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 5, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved a new indication for Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. JARDIANCE is the first type 2 diabetes treatment approved with this additional indication and the only oral type 2 diabetes medicine shown in a clinical trial to provide a life-saving cardiovascular benefit. JARDIANCE is marketed by Boehringer Ingelheim and Eli Lilly and Company (LLY). "As the only diabetes treatment approved by the FDA to reduce the risk of cardiovascular death, JARDIANCE represents a tremendous step forward in our efforts to reduce the impact of heart disease among adults with type 2 diabetes and cardiovascular disease," said Paul Fonteyne, president and CEO, Boehringer Ingelheim Pharmaceuticals, Inc. "This approval is another example of our commitment to the discovery and development of treatment options for adults with type 2 diabetes.